Q-omics provides the consensus-scored ADGRG6 profile across patient tissues and cancer cell-line models. ADGRG6 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ADGRG6 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ADGRG6 RNA expression shows 18,471 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where ADGRG6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADGRG6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADGRG6 survival associations across molecular data types. ADGRG6 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADGRG6 RNA expression–survival associations across cancer types. High ADGRG6 expression shows unfavorable associations in PAAD, UVM and BRCA, but favorable associations in KIRC, BLCA and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for ADGRG6 RNA expression.
This table summarizes ADGRG6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ADGRG6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADGRG6 shows lower tumor expression in LUSC, LIHC, HNSC, LUAD and BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher ADGRG6 RNA expression in tumor versus normal tissue (log2 FC = +1.923, t-test p < 0.001).
This table shows molecular features associated with ADGRG6 in patient tissues and cancer cell lines. In patient samples, ADGRG6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADGRG6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
